The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The trial's primary analysis indicated an 83.7% efficacy ... decision made after consulting with a healthcare provider. The ...

The RSV vaccine isn't needed annually like the flu vaccine ... headache and joint pain. In the combined clinical trials of ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

Clover Biopharmaceuticals Ltd. (HK:2197) has released an update. Clover Biopharmaceuticals announced promising results from its Phase I trial ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

AIM Vaccine will rapidly advance the clinical trials of the mRNA respiratory syncytial virus (RSV) vaccine. As a new and globally heavyweight key vaccine product, this product is expected to become a ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...